CClinicalTrials.gg
WithdrawnNCT04249999ActiOnPACTUKUpdated Sep 19, 2024

ActivOnline: Physical Activity in Cystic Fibrosis Trial UK

An interventional study of ActivOnline in Cystic Fibrosis, sponsored by University of Exeter. Withdrawn at 1 site in United Kingdom. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University of Exeter · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Failure to recruit
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Study summary

Increased level of physical activity (PA) are of benefit in the management of cystic fibrosis (CF). This randomised control tial will assess whether three-months use of an online platform can help increase PA levels in people with CF (compared to a control group continuing routine treatment).

Read the detailed description

Cystic fibrosis (CF) is a genetic condition that predominantly affects the lungs through an accumulation of thick mucus. As there is no cure for CF, it is a disease that is managed through intensive medication, nutrition, physiotherapy, exercise and physical activity (PA).

Increased levels of PA are of benefit to people with CF, and therefore interventions that promote PA are warranted, particularly in adolescence, whereby PA levels decrease. Telehealth interventions are of particular interest in CF, whereby strict cross-infection guidelines prevent patients meeting in person, and allowing patients to overcome geographical barriers at the same time.

Previous research has shown engagement with an online platform (www.activonline.com.au), specifically designed to monitor PA in CF, is feasible and acceptable to people with CF. Therefore, a full randomised control trial is warranted to assess the efficacy of this intervention in changing PA.

UPDATE JUNE 2021: Due to ongoing restrictions placed upon research by the global COVID-19 pandemic, modifications to the protocol are necessary.

Recruitment and consenting will now take place online, and testing procedures will be completed by participants in their own homes. The nature, and length of, intervention remains unchanged.

Changes to protocol approved by ethics board on May 4th 2021.

02

Conditions studied

  • Cystic Fibrosis
03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

Browse Cystic Fibrosis studies →

Lead sponsor

University of Exeter is the lead sponsor of 138 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Confirmed diagnosis of CF
  • Aged 12-35 years (inclusive)
  • Able to provide informed consent/assent
  • Able to access the internet via computer or mobile device

Exclusion criteria

Exclusion Criteria:

  • Presence of severe co-morbidity limiting mobilisation or physical activity participation (e.g. orthopaedic, cardiac or neurological condition)
  • Previous lung transplantation
  • Pregnancy
  • Unable to provide informed consent/assent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intervention

    Access to online physical activity platform (www.activonline.com.au) in addition to usual care.

    Behavioral: ActivOnline

  • No intervention
    Control

    No access to online physical activity platform. Continue with usual care.

Interventions

  • BehavioralActivOnline

    Access to online physical activity platform (www.activonline.com.au)

06

What researchers measure

Primary outcomes

  1. Change in physical activity, objectively measures using ActiGrpah GT9X Link accelerometer.

    Time spent in sedentary, light, moderate and vigorous physical activity domains will be assessed over a one week period. Accelerometer to be worn on non-dominant wrist.

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  2. Change in physical activity, subjectively measured using the Habitual Activity Estimation Scale.

    Questionnaire determines time spent being inactive, somewhat inactive, somewhat active and very active, each reported as a percentage of the day.

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

Secondary outcomes

  1. Change in forced expiratory volume in one second (FEV1), measured in absolute units (L)

    Assessment of lung function

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  2. Change in forced vital capacity (FVC), measured in absolute units (L)

    Assessment of lung function

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  3. Change in forced expiratory volume in one second (FEV1), measured as a percent of predicted, as per GLI2012 equations.

    Assessment of lung function

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  4. Change in forced vital capacity (FVC), measured as a percent of predicted, as per GLI2012 equations.

    Assessment of lung function

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  5. Change in exercise attitudes, measured using the Behavioural Regulation in Exercise Questionnaire.

    Assessment of reasons underlying people's decision to engage, or not engage, in exercise. Scores range from -24 to +20, where a higher score indicates greater exercise autonomy (better outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  6. Change in quality of life, measured using age-specific Cystic Fibrosis Questionnaire (Revised).

    Subjective assessment of health related quality of life, scored from 0 to 100 where a higher score indicates higher quality of life (better outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  7. Change in anxiety, measured using Hospital Anxiety and Depression Scale.

    Subjective report of anxiety, scored from 0 to 21, where a higher score indicates higher anxiety (worse outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  8. Change in depression, measured using Hospital Anxiety and Depression Scale.

    Subjective report of depression, scored from 0 to 21, where a higher score indicates higher depression (worse outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  9. Change in depression, measured using Center for Epidemiological Studies-Depression Scale.

    Subjective reports of anxiety and depression, scored from 0 to 60 where a higher score indicates greater depressive symptoms (worse outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

  10. Change in sleep quality, measured using Pittsburgh Sleep Quality Index (PSQI).

    Subjective report of sleep quality, scored from 0 to 21 where a higher score indicates worse sleep quality (worse outcome).

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks).

Other outcomes

  1. Qualitative assessment of barriers and facilitators to physical activity

    Semi-structured, 10-item interview for participants in both intervention and control group

    Time frame: 3-months post-intervention (+24 weeks)

  2. Qualitative assessment of Activ Online programme

    Semi-structured interview question for participants assigned to intervention group

    Time frame: 3-months post-intervention (+24 weeks)

  3. Usage of Activ Online programme

    Frequency of access and logging of physical activity data

    Time frame: Post-intervention (+12 weeks)

  4. Changes in physical activity, measured by Sport England Short Active Lives Survey.

    Subjective assessment of physical activity

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks)

  5. Changes in physical activity, measured by Sport England Engagement in Sport Questions

    Subjective assessment of physical activity

    Time frame: Baseline, post-intervention (+12 weeks), 3-months post-intervention (+24 weeks)

07

Study locations

1 site
  • University of Exeter
    Exeter, Devon EX1 2LU, United Kingdom
08

References and documents

Publications

  • Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Feasibility and acceptability of an internet-based program to promote physical activity in adults with cystic fibrosis. Respir Care. 2015 Mar;60(3):422-9. doi: 10.4187/respcare.03165. Epub 2014 Nov 25. PubMed 25425703 ↗
  • Cox NS, Eldridge B, Rawlings S, Dreger J, Corda J, Hauser J, Button BM, Bishop J, Nichols A, Middleton A, Ward N, Dwyer T, Tomlinson OW, Denford S, Barker AR, Williams CA, Kingsley M, O'Halloran P, Holland AE; Youth Activity Unlimited - A Strategic Research Centre of the UK Cystic Fibrosis Trust. A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial. BMC Pulm Med. 2019 Dec 19;19(1):253. doi: 10.1186/s12890-019-0942-3. PubMed 31856791 ↗
  • Tomlinson OW, Barker AR, Denford S, Williams CA. Adapting, restarting, and terminating a randomised control trial for people with cystic fibrosis: Reflections on the impact of the COVID-19 pandemic upon research in a clinical population. Contemp Clin Trials Commun. 2024 Mar 27;39:101294. doi: 10.1016/j.conctc.2024.101294. eCollection 2024 Jun. PubMed 38577655 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04249999
Lead sponsor
University of Exeter
Collaborators
Cystic Fibrosis Trust, Sport England, Monash University
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
May 7, 2020
Primary completion
Sep 2021 (estimated)
Completion
Sep 1, 2021
Last update
Sep 19, 2024

Study contacts

Craig A Williams, PhD
principal investigator · University of Exeter

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion